ECSP045430A - Terapia de combinación para el tratamiento de cancer - Google Patents

Terapia de combinación para el tratamiento de cancer

Info

Publication number
ECSP045430A
ECSP045430A EC2004005430A ECSP045430A ECSP045430A EC SP045430 A ECSP045430 A EC SP045430A EC 2004005430 A EC2004005430 A EC 2004005430A EC SP045430 A ECSP045430 A EC SP045430A EC SP045430 A ECSP045430 A EC SP045430A
Authority
EC
Ecuador
Prior art keywords
combination therapy
cancer treatment
amount
patient
need
Prior art date
Application number
EC2004005430A
Other languages
English (en)
Inventor
George Sgouros
Victoria M Richon
Paul A Marks
Richard A Rifkind
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of ECSP045430A publication Critical patent/ECSP045430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La presente invención se relaciona con un método para el tratamiento de cáncer en un paciente necesitado de ello. El método comprende administrar a un paciente necesitado de ello una primer cantidad de un inhibidor de histona deacetilaza en un primer procedimiento de tratamiento, y una segunda cantidad o dosis de radiación en un segundo procedimiento de tratamiento. El primer y segundo tratamiento juntos comprenden una cantidad terapéuticamente efectiva. La combinación del inhibidor HDAC y la terapia de radiación es terapéuticamente sinergística.
EC2004005430A 2002-04-15 2004-11-15 Terapia de combinación para el tratamiento de cancer ECSP045430A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37303302P 2002-04-15 2002-04-15

Publications (1)

Publication Number Publication Date
ECSP045430A true ECSP045430A (es) 2005-05-30

Family

ID=29250948

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005430A ECSP045430A (es) 2002-04-15 2004-11-15 Terapia de combinación para el tratamiento de cancer

Country Status (11)

Country Link
US (2) US20040018968A1 (es)
EP (1) EP1501489A4 (es)
JP (2) JP2005530734A (es)
CN (1) CN100566711C (es)
AU (1) AU2003226408B2 (es)
BR (1) BR0309280A (es)
CA (1) CA2482508A1 (es)
EC (1) ECSP045430A (es)
IL (1) IL164599A0 (es)
MX (1) MXPA04010199A (es)
WO (1) WO2003088954A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
US20040087657A1 (en) * 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
EP1487426B1 (en) * 2002-03-04 2012-08-22 Sloan-kettering Institute For Cancer Research Methods of inducing terminal differentiation
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US8299126B2 (en) * 2003-02-27 2012-10-30 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
EP2060274B1 (en) 2003-04-30 2014-03-26 Ramot at Tel-Aviv University Ltd. Method and device for radiotherapy
US7056883B2 (en) * 2003-06-27 2006-06-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
NZ560485A (en) * 2003-08-26 2009-03-31 Merck Hdac Res Llc Methods of treating cancer with HDAC inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006034207A2 (en) * 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
AU2005302291B2 (en) * 2004-11-02 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2522396A1 (en) * 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
NZ548087A (en) * 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
EP1896436A2 (en) * 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN101189003B (zh) 2005-05-13 2012-02-08 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US20080319045A1 (en) * 2005-10-24 2008-12-25 Novartis Ag Combination of Histone Deacetylase Inhibitors and Radiation
EP1942907A2 (en) * 2005-11-04 2008-07-16 Merck and Co., Inc. Methods of using saha and erlotinib for treating cancer
WO2007056135A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Method of treating cancers with saha and pemetrexed
EP2361619A1 (en) * 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2008013589A2 (en) * 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
CN101528212A (zh) * 2006-09-28 2009-09-09 默克公司 Hdac抑制剂和可螯合的金属化合物的药物组合物以及金属-hdac抑制剂螯合物
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
MX2009006969A (es) * 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
CA2700173C (en) * 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2011053700A1 (en) 2009-10-28 2011-05-05 Henry Ford Health System Methods to mitigate injury from radiation exposure
BR112012022243A8 (pt) * 2010-03-08 2021-11-09 Spectrum Pharmaceuticals Inc Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
ES2755909T3 (es) 2010-07-12 2020-04-24 Celgene Corp Formas sólidas de la romidepsina y sus usos
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
RU2478374C1 (ru) * 2012-02-06 2013-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ внутриполостной терапии при лечении больных с метастазами рака во влагалище
US8836679B2 (en) * 2012-08-06 2014-09-16 Au Optronics Corporation Display with multiplexer feed-through compensation and methods of driving same
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103159646B (zh) * 2013-03-19 2014-10-22 广东药学院 一种异羟肟酸类化合物及其制备方法和应用
CN105658809B (zh) * 2013-04-09 2020-03-27 伊利诺伊大学董事会 肿瘤选择性联合疗法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
US10231941B2 (en) 2015-01-23 2019-03-19 Temple University—Of The Commonwealth System of Higher Educaton Use of short chain fatty acids in cancer prevention
CN104788391B (zh) * 2015-04-21 2017-03-08 中国医学科学院医药生物技术研究所 肉桂酰中性红酰胺(ca‑pz)及其制备与应用
US20210322415A1 (en) * 2016-02-15 2021-10-21 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
WO2018207105A1 (en) 2017-05-11 2018-11-15 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
US11969485B2 (en) 2018-04-02 2024-04-30 Alpha Tau Medical Ltd. Controlled release of radionuclides
CA3114299A1 (en) * 2018-11-01 2020-05-07 Alpha Tau Medical Ltd. Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化
EP4213826A1 (en) * 2020-09-15 2023-07-26 Oncoinvent AS Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
EP4251214A4 (en) * 2020-11-25 2025-01-08 Actinium Pharmaceuticals, Inc. METHODS OF TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS
CA3202211A1 (en) 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
IL142531A0 (en) * 1998-10-13 2002-03-10 Fujisawa Pharmaceutical Co Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
DE60038624T2 (de) * 1999-10-07 2009-06-10 Aquilar-Cordova, Carlos, Estuardo, Newton Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
AU783504C (en) * 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
EP1438404A2 (en) * 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
US6905699B2 (en) * 2000-07-06 2005-06-14 Sumitomo Chemical Company, Limited Insecticides
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002022133A1 (en) * 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6693132B2 (en) * 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
WO2002076941A2 (en) * 2001-03-27 2002-10-03 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20040142859A1 (en) * 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
US20040087657A1 (en) * 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
EP1487426B1 (en) * 2002-03-04 2012-08-22 Sloan-kettering Institute For Cancer Research Methods of inducing terminal differentiation
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
JP2005530734A (ja) * 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
NZ560485A (en) * 2003-08-26 2009-03-31 Merck Hdac Res Llc Methods of treating cancer with HDAC inhibitors
EP1667680A4 (en) * 2003-08-29 2008-10-08 Aton Pharma Inc COMBINATION PROCEDURE FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
CN1728991A (zh) 2006-02-01
JP2005530734A (ja) 2005-10-13
MXPA04010199A (es) 2005-07-05
CN100566711C (zh) 2009-12-09
AU2003226408B2 (en) 2007-06-14
US20090054720A1 (en) 2009-02-26
EP1501489A1 (en) 2005-02-02
HK1086488A1 (zh) 2006-09-22
JP2009114207A (ja) 2009-05-28
BR0309280A (pt) 2005-02-22
WO2003088954A1 (en) 2003-10-30
AU2003226408A1 (en) 2003-11-03
CA2482508A1 (en) 2003-10-30
IL164599A0 (en) 2005-12-18
EP1501489A4 (en) 2007-11-21
US20040018968A1 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
CR8163A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
CY1106259T1 (el) Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
CO5590913A2 (es) Terapia de combinacion antivirica
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
WO2023164455A3 (en) Compositions and methods to modulate the immune system
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
Aziz-Jalali et al. Efficacy of intralesional bleomycin in the treatment of resistant warts